The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oncology urgent care to decrease unnecessary emergency room visits.
 
Maura Abbott
No Relationships to Disclose
 
Laureen Hill
No Relationships to Disclose
 
Deepa Kumaraiah
No Relationships to Disclose
 
Christina Russomanno
No Relationships to Disclose
 
Yelena Ustoyev
No Relationships to Disclose
 
Danielle Drimer Katayen
No Relationships to Disclose
 
Kate Kaley
No Relationships to Disclose
 
Kristina Howard
No Relationships to Disclose
 
Maria Negron
No Relationships to Disclose
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer
Honoraria - Array BioPharma; Bayer; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Consulting or Advisory Role - Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Gencirq; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Daiichi Sankyo; Iovance Biotherapeutics; PTC Therapeutics; PureTech